Home Healthcare Pharmaceuticals Cephalosporin Drugs Market

Cephalosporin Drugs Market Size, Share & Trends Analysis Report By Generation (First-generation Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, Fifth-generation Cephalosporin), By Route of Drug Administration (Injection, Oral, Others), By Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cephalosporin Drugs Market, By Generation 2022-2034 (USD MILLION/ Units)
    1. First-generation Cephalosporin
    2. Second-generation Cephalosporin
    3. Third-generation Cephalosporin
    4. Fourth-generation Cephalosporin
    5. Fifth-generation Cephalosporin
  2. Cephalosporin Drugs Market, By Route of Drug Administration 2022-2034 (USD MILLION/ Units)
    1. Injection
    2. Oral
    3. Others
  3. Cephalosporin Drugs Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Respiratory Tract Infection
    2. Skin Infection
    3. Ear Infection
    4. Urinary Tract Infection
    5. Sexually Transmitted Infection
    6. Others
  4. Regional Cephalosporin Drugs Market
    1. North America
      1. North America Cephalosporin Drugs Market By Generation 2022-2034 (USD MILLION/ Units)
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
      2. North America Cephalosporin Drugs Market By Route of Drug Administration 2022-2034 (USD MILLION/ Units)
        1. Injection
        2. Oral
        3. Others
      3. North America Cephalosporin Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Respiratory Tract Infection
        2. Skin Infection
        3. Ear Infection
        4. Urinary Tract Infection
        5. Sexually Transmitted Infection
        6. Others
      4. U.S.
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      5. Canada
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
    2. Europe
      1. Europe Cephalosporin Drugs Market By Generation 2022-2034 (USD MILLION/ Units)
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
      2. Europe Cephalosporin Drugs Market By Route of Drug Administration 2022-2034 (USD MILLION/ Units)
        1. Injection
        2. Oral
        3. Others
      3. Europe Cephalosporin Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Respiratory Tract Infection
        2. Skin Infection
        3. Ear Infection
        4. Urinary Tract Infection
        5. Sexually Transmitted Infection
        6. Others
      4. U.K.
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      5. Germany
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      6. France
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      7. Spain
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      8. Italy
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      9. Russia
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      10. Nordic
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      11. Benelux
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      12. Rest of Europe
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
    3. APAC
      1. APAC Cephalosporin Drugs Market By Generation 2022-2034 (USD MILLION/ Units)
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
      2. APAC Cephalosporin Drugs Market By Route of Drug Administration 2022-2034 (USD MILLION/ Units)
        1. Injection
        2. Oral
        3. Others
      3. APAC Cephalosporin Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Respiratory Tract Infection
        2. Skin Infection
        3. Ear Infection
        4. Urinary Tract Infection
        5. Sexually Transmitted Infection
        6. Others
      4. China
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      5. Korea
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      6. Japan
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      7. India
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      8. Australia
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      9. Taiwan
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      10. South East Asia
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      11. Rest of Asia-Pacific
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
    4. Middle East and Africa
      1. Middle East and Africa Cephalosporin Drugs Market By Generation 2022-2034 (USD MILLION/ Units)
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
      2. Middle East and Africa Cephalosporin Drugs Market By Route of Drug Administration 2022-2034 (USD MILLION/ Units)
        1. Injection
        2. Oral
        3. Others
      3. Middle East and Africa Cephalosporin Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Respiratory Tract Infection
        2. Skin Infection
        3. Ear Infection
        4. Urinary Tract Infection
        5. Sexually Transmitted Infection
        6. Others
      4. UAE
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      5. Turkey
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      6. Saudi Arabia
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      7. South Africa
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      8. Egypt
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      9. Nigeria
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      10. Rest of MEA
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
    5. LATAM
      1. LATAM Cephalosporin Drugs Market By Generation 2022-2034 (USD MILLION/ Units)
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
      2. LATAM Cephalosporin Drugs Market By Route of Drug Administration 2022-2034 (USD MILLION/ Units)
        1. Injection
        2. Oral
        3. Others
      3. LATAM Cephalosporin Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Respiratory Tract Infection
        2. Skin Infection
        3. Ear Infection
        4. Urinary Tract Infection
        5. Sexually Transmitted Infection
        6. Others
      4. Brazil
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      5. Mexico
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      6. Argentina
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      7. Chile
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      8. Colombia
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
      9. Rest of LATAM
        1. First-generation Cephalosporin
        2. Second-generation Cephalosporin
        3. Third-generation Cephalosporin
        4. Fourth-generation Cephalosporin
        5. Fifth-generation Cephalosporin
        6. Injection
        7. Oral
        8. Others
        9. Respiratory Tract Infection
        10. Skin Infection
        11. Ear Infection
        12. Urinary Tract Infection
        13. Sexually Transmitted Infection
        14. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.